ProfileGDS5678 / 1428804_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 60% 56% 59% 54% 56% 61% 58% 61% 57% 66% 67% 64% 73% 59% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 13.6316560
GSM967853U87-EV human glioblastoma xenograft - Control 23.3950356
GSM967854U87-EV human glioblastoma xenograft - Control 33.5501359
GSM967855U87-EV human glioblastoma xenograft - Control 43.288454
GSM967856U87-EV human glioblastoma xenograft - Control 53.3700956
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 13.74961
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 23.5839658
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 33.661661
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 43.4300157
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 14.0179966
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 24.0455767
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 33.8121664
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 44.6739173
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 53.5370959